Get the Stockscreener App
14.55
2.48%
-0.37
After Hours:
14.46
-0.09
-0.62%
Intellia Therapeutics Inc stock is traded at $14.55, with a volume of 8.64M.
It is down -2.48% in the last 24 hours and up +6.44% over the past month.
Intellia Therapeutics is a gene-editing company focused on the development of Crispr/Cas9-based therapeutics. Crispr/Cas9 stands for Clustered Regularly Interspaced Short Palindromic Repeats (Crispr)/Crispr-associated protein 9 (Cas9), which is a revolutionary technology for precisely altering specific sequences of genomic DNA. Intellia is focused on using this technology to treat genetically defined diseases. It's evaluating multiple gene editing approaches using in vivo and ex vivo therapies to address diseases with high unmet medical needs, including ATTR amyloidosis, hereditary angioedema, sickle cell disease, and immuno-oncology. Intellia has formed collaborations with several companies to advance its pipeline, including narrow-moat Regeneron and wide-moat Novartis.
See More
Previous Close:
$14.92
Open:
$14.78
24h Volume:
8.64M
Relative Volume:
1.48
Market Cap:
$2.03B
Revenue:
$67.67M
Net Income/Loss:
$-412.69M
P/E Ratio:
-3.8023
EPS:
-3.8266
Net Cash Flow:
$-395.87M
1W Performance:
+12.88%
1M Performance:
+6.44%
6M Performance:
+59.54%
1Y Performance:
+62.39%
1-Day Range:
$13.54
$14.92
1-Week Range:
$11.81
$15.00
52-Week Range:
$7.95
$28.25
Intellia Therapeutics Inc Stock (NTLA) Company Profile
Name
Intellia Therapeutics Inc
Sector
Industry
Phone
857-285-6200
Address
40 ERIE STREET, CAMBRIDGE, MA
Compare NTLA vs VRTX, REGN, ARGX, ALNY, RVMD
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
NTLA
Intellia Therapeutics Inc
|
14.55 | 2.08B | 67.67M | -412.69M | -395.87M | -3.8266 |
VRTX
Vertex Pharmaceuticals Inc
|
453.17 | 114.33B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
614.73 | 64.47B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
878.49 | 54.99B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
281.90 | 38.42B | 4.29B | 577.22M | 641.34M | 4.2086 |
RVMD
Revolution Medicines Inc
|
156.58 | 34.03B | 742.00K | -1.37B | -1.07B | -7.0731 |
Intellia Therapeutics Inc Stock (NTLA) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Mar-02-26 | Upgrade | William Blair | Mkt Perform → Outperform |
| Nov-12-25 | Downgrade | Wolfe Research | Outperform → Peer Perform |
| Nov-11-25 | Downgrade | Evercore ISI | Outperform → In-line |
| Nov-07-25 | Downgrade | JP Morgan | Neutral → Underweight |
| Oct-28-25 | Downgrade | Bernstein | Outperform → Mkt Perform |
| Oct-28-25 | Downgrade | RBC Capital Mkts | Outperform → Sector Perform |
| Oct-27-25 | Downgrade | Guggenheim | Buy → Neutral |
| Oct-27-25 | Downgrade | William Blair | Outperform → Mkt Perform |
| Oct-06-25 | Upgrade | Citizens JMP | Mkt Perform → Mkt Outperform |
| Apr-21-25 | Upgrade | Wolfe Research | Peer Perform → Outperform |
| Mar-05-25 | Initiated | H.C. Wainwright | Buy |
| Feb-28-25 | Downgrade | Goldman | Neutral → Sell |
| Feb-28-25 | Downgrade | JP Morgan | Overweight → Neutral |
| Jan-27-25 | Downgrade | Morgan Stanley | Overweight → Equal-Weight |
| Feb-23-24 | Downgrade | Goldman | Buy → Neutral |
| Feb-15-24 | Initiated | Wolfe Research | Peer Perform |
| Apr-13-23 | Initiated | Canaccord Genuity | Buy |
| Mar-21-23 | Initiated | Bernstein | Outperform |
| Mar-14-23 | Upgrade | BMO Capital Markets | Market Perform → Outperform |
| Feb-01-23 | Initiated | Cantor Fitzgerald | Overweight |
| Jan-24-23 | Upgrade | Citigroup | Sell → Neutral |
| Jan-19-23 | Downgrade | JMP Securities | Mkt Outperform → Mkt Perform |
| Oct-11-22 | Initiated | Morgan Stanley | Overweight |
| Sep-21-22 | Initiated | JP Morgan | Overweight |
| Sep-01-22 | Initiated | Citigroup | Sell |
| Jun-17-22 | Initiated | BMO Capital Markets | Market Perform |
| Jun-16-22 | Initiated | BofA Securities | Buy |
| Apr-28-22 | Initiated | Credit Suisse | Outperform |
| Feb-18-22 | Initiated | William Blair | Outperform |
| Feb-07-22 | Upgrade | Oppenheimer | Perform → Outperform |
| Jan-31-22 | Initiated | Cowen | Outperform |
| Jan-07-22 | Initiated | Piper Sandler | Overweight |
| Oct-05-21 | Initiated | Guggenheim | Buy |
| Sep-24-21 | Initiated | Stifel | Buy |
| Jun-28-21 | Reiterated | H.C. Wainwright | Buy |
| Jun-11-21 | Initiated | H.C. Wainwright | Buy |
| May-07-21 | Upgrade | ROTH Capital | Neutral → Buy |
| May-04-21 | Initiated | RBC Capital Mkts | Outperform |
| Mar-04-21 | Initiated | JMP Securities | Mkt Outperform |
| Dec-22-20 | Downgrade | Robert W. Baird | Outperform → Neutral |
| Oct-27-20 | Initiated | Truist | Buy |
| Oct-14-20 | Initiated | Wells Fargo | Overweight |
| Sep-18-20 | Initiated | Goldman | Buy |
| Feb-28-20 | Upgrade | Oppenheimer | Perform → Outperform |
| Feb-14-20 | Downgrade | Wedbush | Outperform → Neutral |
| Nov-01-19 | Upgrade | Raymond James | Mkt Perform → Outperform |
| Jul-09-19 | Initiated | Robert W. Baird | Outperform |
| Jun-10-19 | Initiated | ROTH Capital | Neutral |
| May-03-19 | Upgrade | Wedbush | Neutral → Outperform |
| Apr-12-19 | Initiated | Evercore ISI | Outperform |
| Nov-02-18 | Downgrade | Wedbush | Outperform → Neutral |
| Oct-29-18 | Initiated | Credit Suisse | Neutral |
| Sep-21-18 | Initiated | Raymond James | Mkt Perform |
| May-15-18 | Upgrade | Chardan Capital Markets | Neutral → Buy |
| Mar-08-18 | Initiated | JMP Securities | Mkt Outperform |
| Nov-01-17 | Reiterated | Jefferies | Buy |
| Jun-22-17 | Resumed | Jefferies | Buy |
| Mar-28-17 | Initiated | Chardan Capital Markets | Buy |
| Aug-05-16 | Upgrade | Jefferies | Hold → Buy |
View All
Intellia Therapeutics Inc Stock (NTLA) Latest News
Canaccord reiterates Intellia stock rating on positive trial data By Investing.com - Investing.com Canada
BofA Securities Maintains Intellia Therapeutics(NTLA.US) With Hold Rating, Maintains Target Price $19 - Moomoo
Analysts’ Top Healthcare Picks: Intellia Therapeutics (NTLA), Electrocore (ECOR) - The Globe and Mail
Intellia Therapeutics (NTLA) Skyrockets 23% on Encouraging Lonvo-Z Results - Insider Monkey
Intellia Therapeutics Stock Jumps as CRISPR Therapy Data Put FDA Filing in Focus - TechStock²
Intellia Therapeutics jumps after additional Phase 3 HAE data and peer-reviewed publication reinforce lonvo-z outlook - Quiver Quantitative
Why is Intellia Therapeutics stock surging today? By Investing.com - Investing.com Canada
Why Is NTLA Stock Jumping 5% Premarket Today? - Stocktwits
Intellia Therapeutics | 8-K: Current report - Moomoo
NTLA Reiterated by Wedbush -- Price Target Maintained at $12.00 - GuruFocus
NTLA Reiterated by Citizens -- Price Target Maintained at $30 - GuruFocus
Intellia Therapeutics options trading jumps to 7,041 contracts - Investing.com
Intellia Therapeutics options trading jumps to 7,041 contracts By Investing.com - Investing.com India
Goldman Sachs Maintains Intellia Therapeutics(NTLA.US) With Sell Rating, Maintains Target Price $9 - Moomoo
Intellia's One-Time Gene Editing Therapy Gains Ground Against Rivals In Rare Swelling Disorder - Benzinga
Intellia Reports Strong Phase 3 Results for lonvo-z, 87% fewer monthly attacks; BLA rolling, U.S. launch H1 2027 - TradingView
Phase 3 HAELO data support Intellia (NTLA) lonvo-z as potential one-time therapy - Stock Titan
Why is NTLA stock jumping 5% premarket today? - MSN
H.C. Wainwright reiterates Intellia stock rating on positive trial data - Investing.com
H.C. Wainwright reiterates Intellia stock rating on positive trial data By Investing.com - Investing.com Canada
Positive Phase III results for Intellia’s lonvo-z - The Pharma Letter
NTLA Reiterated by HC Wainwright & Co. -- Price Target Maintained at $25 - GuruFocus
Citizens reiterates Intellia stock rating on positive trial data By Investing.com - Investing.com Nigeria
Citizens reiterates Intellia stock rating on positive trial data - Investing.com
William Blair Maintains Intellia Therapeutics(NTLA.US) With Buy Rating - Moomoo
NTLA Stock Surges 35% Overnight: Retail Mood Peaks Ahead Of First-Ever Phase 3 Readout For Gene-Editing Therapy - Stocktwits
Intellia Therapeutics (NTLA) down 7.9% since last earnings report: Can it rebound? - MSN
Intellia Therapeutics (NTLA) Reports Promising Phase 3 Trial Res - GuruFocus
NTLA Jumps Premarket On Positive Late-Stage Trial Data For Gene-Editing Therapy — Retail Says Buy Now Before It’s Too Late - Stocktwits
Intellia presents Phase 3 results for HAE gene therapy lonvo-z - Investing.com UK
Intellia Therapeutics Reports Additional Positive Phase 3 Results for Lonvoguran Ziclumeran (lonvo-z) in Patients with Hereditary Angioedema - Intellia Therapeutics
Intellia presents Phase 3 results for HAE gene therapy lonvo-z By Investing.com - Investing.com India
Intellia Therapeutics Says Haleo Met Its Primary Endpoint With An 87% Reduction (P - TradingView
One-time CRISPR gene edit cuts HAE attacks by 87% in Phase 3 trial - Stock Titan
Intellia Shareholders Back Board, Executive Pay and Auditor - The Globe and Mail
Exploring High Growth Tech Stocks In The US Market - simplywall.st
Intellia Therapeutics | 4: Statement of changes in beneficial ownership of securities-Director Bhanji Muna - Moomoo
Intellia (NTLA) director receives 9,200 RSUs and 13,300 options - Stock Titan
Intellia (NTLA) director Georgia Keresty receives stock awards and options grant - Stock Titan
Intellia Therapeutics (NTLA) director receives stock and option awards - Stock Titan
Intellia (NTLA) director Brian Goff receives RSU and stock option grants - Stock Titan
Intellia Therapeutics (NTLA) director receives 9,200 RSUs and 13,300 stock options - Stock Titan
Intellia (NTLA) director awarded RSUs and stock options in new grant - Stock Titan
Intellia (NTLA) director Muna Bhanji granted 9,200 RSUs and 13,300 options - Stock Titan
Intellia Therapeutics (NTLA) posts 2026 shareholder voting results - Stock Titan
Intellia Therapeutics (NTLA) Down 7.9% Since Last Earnings Report: Can It Rebound? - Yahoo Finance Singapore
Draft FDA guidance could be a boon for gene therapy developers - MSN
Intellia Therapeutics Stock Short Interest Rises to 46.78% - Quiver Quantitative
Intellia Therapeutics Inc Annual Shareholders Meeting Transcript - GuruFocus
Intellia Therapeutics, Inc. Trade Ideas — XETR:38I - TradingView
Average basic shares outstanding of Intellia Therapeutics, Inc. – XETR:38I - TradingView
Intellia Therapeutics Inc Stock (NTLA) Financials Data
Revenue
Net Income
Cash Flow
EPS
Intellia Therapeutics Inc Stock (NTLA) Insider Trading
| Insider Trading | Relationship | Date | Transaction | Cost | #Shares | Value ($) | #Shares Total |
|---|---|---|---|---|---|---|---|
| Clark Eliana | EVP, Chief Technical Officer |
Mar 02 '26 |
Sale |
13.78 |
607 |
8,364 |
93,864 |
| LEONARD JOHN M | President and CEO |
Jan 05 '26 |
Sale |
9.21 |
34,146 |
314,485 |
1,013,339 |
| Schultes Birgit C | EVP, Chief Scientific Officer |
Jan 05 '26 |
Sale |
9.21 |
8,508 |
78,359 |
98,533 |
| BASTA JAMES | EVP, General Counsel |
Jan 05 '26 |
Sale |
9.21 |
10,397 |
95,756 |
101,528 |
| Cohen Fred E | Director |
Jan 05 '26 |
Buy |
9.35 |
150,000 |
1,402,500 |
207,453 |
| Lebwohl David | EVP, Chief Medical Officer |
Jan 05 '26 |
Sale |
9.21 |
11,903 |
109,627 |
121,249 |
| Clark Eliana | EVP, Chief Technical Officer |
Jan 05 '26 |
Sale |
9.21 |
9,515 |
87,633 |
87,118 |
| Dulac Edward J III | EVP, Chief Financial Officer |
Jan 05 '26 |
Sale |
9.21 |
6,379 |
58,751 |
99,683 |
| Dube Michael P | VP, Chief Accounting Officer |
Jan 05 '26 |
Sale |
9.21 |
2,989 |
27,529 |
52,277 |
| LEONARD JOHN M | President and CEO |
Dec 11 '25 |
Option Exercise |
6.83 |
49,959 |
341,220 |
1,127,074 |
1.27%
1.43%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):